Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 47, Issue -, Pages 1557-1565Publisher
PORTLAND PRESS LTD
DOI: 10.1042/BST20190763
Keywords
-
Categories
Funding
- British Heart Foundation [BHF/TARGETPDE/PG/17/26/32881]
- Medical Research Council [MC-PC-13063, MC-PC-15039]
- MVLS doctoral training programme at University of Glasgow
- MRC [MC_PC_13063, MC_PC_15039] Funding Source: UKRI
Ask authors/readers for more resources
Phosphodiesterases (PDEs) have long been considered as targets for the treatment of Alzheimer's disease (AD) and a substantial body of evidence suggests that one subfamily from the super-family of PDEs, namely PDE4D, has particular significance in this context. This review discusses the role of PDE4 in the orchestration of cAMP response element binding signaling in AD and outlines the benefits of targeting PDE4D specifically. We examine the limited available literature that suggests PDE4 expression does not change in AD brains together with reports that show PDE4 inhibition as an effective treatment in this age-related neurodegenerative disease. Actually, aging induces changes in PDE4 expression/activity in an isoform and brain-region specific manner that proposes a similar complexity in AD brains. Therefore, a more detailed account of AD-related alterations in cellular/tissue location and the activation status of PDE4 is required before novel therapies can be developed to target cAMP signaling in this disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available